Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 7.5 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Ignyta, Lilly, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pfizer, and Takeda Oncology.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
Physicians’ Education Resource ®, LLC.
All rights reserved.

12th Annual New York Lung Cancers Symposium

12th Annual New York Lung Cancers Symposium


November 11, 2017
New York Marriott Marquis
1535 Broadway

New York, NY 10036
(888) 523-0366


Overview

The 12th Annual New York Lung Cancers Symposium is a 1-day educational and scientific meeting that will provide an update on state-of-the-art management of patients with lung cancer, as well as a focus on future therapies in development.

The past decade in lung cancer research has yielded a wealth of therapeutic options for patients with lung cancer, as well as greater knowledge of the many different subtypes of this disease. In particular, agents targeting oncogenic drivers and immunotherapeutic approaches have transformed the management of patients with lung cancer in recent years. Furthermore, numerous investigational approaches are in late-phase evaluation, with the potential to change standards of care in 2016, and beyond. However, although these developments hold the promise to further improve outcomes for patients with lung cancer, they also raise challenges for busy clinicians to maintain state-of-the-art approaches in their practices.

This year’s program, led by world-class thoracic oncologists, Mark G. Kris, MD, and Roman Perez-Soler, MD, will focus on a number of core areas that are key to optimizing care for patients with lung cancer, including targeted therapy, immunotherapy, adjuvant therapy, combined modality therapy, and approaches for challenging subtypes, such as squamous lung cancer. Participants will have an opportunity to learn from engaging presentations delivered by leading experts, as well as apply their knowledge in case-based panel discussions. This fast-paced, highly practical, and interactive forum will once again provide physicians who treat patients with lung cancer unique access to renowned international experts in the management of these tumors.
 

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Ignyta, Lilly, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pfizer, and Takeda Oncology.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.


Target Audience

This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate. 

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  • Determine testing strategies to optimize tumor characterization and inform clinical decision making for the management of patients with lung cancers
  • Identify diagnostic and tumor testing results that inform individualized treatment planning and sequencing for patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
  • Integrate recent clinical trial findings concerning single-agent and combination immunotherapeutic strategies to manage advanced forms of lung cancers
  • Apply personalized approaches to optimize sequencing of oncogenic-driven NSCLC via assessment of mutation subtypes in multiple lines of care
  • Determine frontline and subsequent options in patients without actionable mutations, including the role of chemotherapies and antiangiogenic strategies in these settings
  • Describe methods to proactively plan for and mitigate the impact of treatment-related toxicities in the care of patients with lung cancers


Program Chairs

Mark G. Kris, MD
Attending, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY




Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Cancer Center Director
Albert Einstein College of Medicine
Bronx, NY








Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By